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Many chronic diseases are characterized by excessive oxida-
tive stress and inflammation [1–3]. The recent escalation of
chronic conditions like obesity, insulin resistance, diabetes,
hypertension, and other related cardiometabolic compli-
cations in all ages of the population including children,
adolescences, and adults poses a great challenge to health
care systems [4, 5]. Many cardiometabolic complications
are multifactorial diseases and a wide variety of etiologi-
cal factors including genetic, habitual, environmental, and
epigenetic may be involved [4, 5]. Although these factors
perturb the physiological milieu in different ways, it has been
consistently shown that a common denominator amongst
these factors is the production of increased oxidative stress
and inflammation at various stages during the progression
and development of many cardiometabolic disorders [4–8].
Although significant strides have been made in elucidating
the role of oxidative stress and inflammation in insulin resis-
tance, diabetes, and many cardiometabolic diseases, novel
mechanistic studies are needed to broaden our knowledge on
the treatment and management of these chronic conditions.
This special issue contains review papers and research
articles that address a broad range of mechanistic paradigms
in the pathophysiology of insulin resistance, diabetes, hyper-
tension, obesity, and related cardiometabolic complications.
The role of inflammation and apolipoproteins in the devel-
opment of atherosclerotic plague, thrombosis, and related
cardiac complications has been widely acknowledged [9–11].
Since apolipoproteins play a major pathophysiologi-
cal role in atherosclerosis, in an article featuring in this
special issue, A. J. Lepedda et al. used two-dimensional
electrophoresis (2DE) coupled with Matrix-Assisted Laser
Desorption/Ionization (MALDI), Time of Flight (TOF),
and Mass Spectrometry (MS) analysis to characterize the
apolipoprotein components of very-low-density lipoprotein
(VLDL), low-density lipoprotein (LDL), and high-density
lipoprotein (HDL) from plasma of patients undergoing
carotid endarterectomy. The study of A. J. Lepedda et al.
will unveil novel perspectives on the pathophysiological role
of apolipoproteins in development of atherosclerotic plague.
In another related article featuring in this special issue, W.
Sun et al. showed that a herbal extract obtained from the
medicinal plantMagnolia officinalis attenuated cardiac hyper-
trophy and cardiac dysfunction by reducing myocardial lipid
accumulation, inflammation, oxidative stress, and apoptosis
in animals fed with high-fat diet. Interestingly, the benefit of
Magnolia officinalis is not limited to myocardial dysfunction.
In another study byW. Cui et al. reported in this special issue,
Magnolia officinalis was shown to abate several markers of
inflammation and oxidative stress in the kidneys including
tumor necrosis factor-𝛼, plasminogen activator inhibitor-1,
3-nitrotyrosine, and 4-hydroxy-2-nonenal. Interestingly, the
suppression of these prooxidative/inflammatory agents were
associated with the potentiation of peroxisome proliferator-
activated receptor-𝛾 coactivator-1𝛼 and hexokinase II, with
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improved renal morphology and the reduction of proteinuria
suggesting improved renal function.
An important cytoprotective enzyme with benefits
against diabetes, hypertension, obesity, and related
cardiometabolic complications is heme oxygenase [1–3, 12–
15]. In a related article featuring in this special issue, S. Tiwari
et al. showed that the heme oxygenase system improves
cardiac function by attenuating markers of heart failure,
cardiac hypertrophy/lesions, extracellular matrix/profibrotic
proteins, and inflammatory/oxidative mediators, while
concomitantly enhancing adiponectin and atrial natriuretic
peptide in obese rats with insulin resistance. Similarly, Y.
Son et al. wrote a review article that delineates the protective
mechanisms of heme oxygenase in metabolic diseases.
Furthermore, Md. J. Uddin and coworkers demonstrated
in a research article that carbon monoxide, a product
generated by heme oxygenase, suppressed inflammation
in colitis mice model via inhibition of glycogen synthase
kinase-3, a serine-threonine protein kinase implicated in
glycogen metabolism, and other cellular functions including
apoptosis [16, 17]. Besides the heme oxygenase system, other
molecules including trace elements are important in the
regulation of cardiometabolic functions [18, 19]. Emerging
evidence indicates that perturbations in the delicate balance
of trace elements such as copper and zinc may offset redox
equilibrium in physiological milieu leading to oxidative
stress and eventually to the development of diabetes and
diabetic complications [20–22]. In this special issue, J. Xu
et al. reported novel insights on zinc/copper ratio in patients
with different pathological profiles including impaired
fasting glucose, impaired glucose tolerance type-1 diabetes,
and type-2 diabetes.
Collectively, the articles presented in this special issue
would unveil novel concepts that would stimulate further
research in this area of considerable interest given the
escalation of diabetes, obesity, hypertension, and related
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